Early-stage diagnosis of pancreatic cancer offers opportunity to improve overall patient survival

Background

Pancreatic ductal adenocarcinoma (PDAC) has one of the worst survival rates with only 5% five years survival. By providing physicians with actionable information when the tumour is still resectable, the overall 5 year PDAC patient survival rate could increase from 5 % to 50- 60%. We present a summary of retrospective studies performed on IMMray™ PanCan-d, a blood test developed for early stage diagnosis of pancreatic cancer.

Methods

IMMray™ PanCan-d creates a biological snapshot of an individual's immune response by analysing serum proteins that change as a sign of disease. The process to derive unique biomarker immunosignatures from an antibody microarray platform, through state of the art bioinformatics algorithms, is also presented.

Results

Based on recent results from the largest retrospective study on pancreas cancer covering 1400 blood samples, we have been able to differentiate 148 asymptomatic patients in stage I and II from 890 healthy individuals controls with 96% accuracy*. Furthermore, when analyzing all stages of pancreatic cancer in retrospective studies covering more than 3000 blood samples, the test accuracy is as high as 98%. *Manuscript in preparation

Conclusions

IMMray PanCan-d can detect asymptomatic pancreatic cancer patients stage 1 and 2 with 96% accuracy and stage 1 to 4 with 98% accuracy.

Clinical trial identification

Legal entity responsible for the study

Lund University, Create Health, Dept. of Immunotechnology

Funding

Lund University, Create Health, Dept. of Immunotechnology

Disclosure

L. Dexlin Mellby, A. Holmér: Employee at Immunovia AB. All authors have declared no conflicts of interest.